Furthermore, researchers are increasingly finding clinical utility for sVEGFR1, either independently or in combination with circulating VEGF or PlGF, as diagnostic and prognostic markers for a diversity of angiogenesis-dependent medical conditions: from astrocytic gliomas [37], primary breast cancer [38], acute myeloid leukemia [39], to sepsis [40], and pre-eclampsia [41], [42]. This evidence concerns the gene VEGFA and acute myeloid leukemia.